We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Pfizer, American Tower Corp, Intuitive Surgical, Fidelity National Information Services and FedEx
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 8, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , American Tower Corporation (AMT - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) , Fidelity National Information Services, Inc. (FIS - Free Report) and FedEx Corporation (FDX - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Pfizer, American Tower and Intuitive Surgical
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, American Tower Corp, and Intuitive Surgical. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Pfizer have outperformed the Zacks Large-Cap Pharmaceuticals industry over the past year (+25% vs. +16%). The Zacks analyst believes that Pfizer looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years, which can drive long-term growth.
The Consumer Healthcare JV with Glaxo and merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Its COVID-19 vaccine candidate is now approved for emergency use in several countries and has become a key contributor to the top line. Pricing pressure, currency headwinds, and stiff competition in the immuno-oncology market remain as some of the major concerns though.
American Tower shares have gained +12.8% in the last six months against the Zacks REIT and Equity Trust industry’s gain of +8.8%. The Zacks analyst believes that the company is likely to benefit from increased investment by wireless carriers in 4G LTE and 5G networks.
Solid business fundamentals, prudent capital-allocation strategy as well as steady dividend payouts are encouraging. American Tower is rapidly expanding in the international markets, especially in the emerging Asian and Latin American markets. Tower operations in such markets, however, are not as profitable as that in the mature U.S. market. Stiff competition from other tower companies is another concern.
Shares of Intuitive Surgical have gained +5.6% over the past three months against the Zacks Medical Instruments industry’s loss of -9%. The Zacks analyst believes that growing adoption of the da Vinci system, improving procedure volumes, as well as a solid recurring revenue base are some of the major headwinds.
The company’s revenue growth in the second quarter of 2021 indicated procedure growth as well as higher-than-expected system placements. Strong segmental performance was also witnessed during the quarter. Stiff competition in the global MedTech space, increased production cost due to the pandemic and risks related to procedure adoption remain as major concerns though.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Pfizer, American Tower Corp, Intuitive Surgical, Fidelity National Information Services and FedEx
For Immediate Release
Chicago, IL – October 8, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , American Tower Corporation (AMT - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) , Fidelity National Information Services, Inc. (FIS - Free Report) and FedEx Corporation (FDX - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Pfizer, American Tower and Intuitive Surgical
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, American Tower Corp, and Intuitive Surgical. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Pfizer have outperformed the Zacks Large-Cap Pharmaceuticals industry over the past year (+25% vs. +16%). The Zacks analyst believes that Pfizer looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years, which can drive long-term growth.
The Consumer Healthcare JV with Glaxo and merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Its COVID-19 vaccine candidate is now approved for emergency use in several countries and has become a key contributor to the top line. Pricing pressure, currency headwinds, and stiff competition in the immuno-oncology market remain as some of the major concerns though.
(You can read the full research report on Pfizer here >>>)
American Tower shares have gained +12.8% in the last six months against the Zacks REIT and Equity Trust industry’s gain of +8.8%. The Zacks analyst believes that the company is likely to benefit from increased investment by wireless carriers in 4G LTE and 5G networks.
Solid business fundamentals, prudent capital-allocation strategy as well as steady dividend payouts are encouraging. American Tower is rapidly expanding in the international markets, especially in the emerging Asian and Latin American markets. Tower operations in such markets, however, are not as profitable as that in the mature U.S. market. Stiff competition from other tower companies is another concern.
(You can read the full research report on American Tower here >>>)
Shares of Intuitive Surgical have gained +5.6% over the past three months against the Zacks Medical Instruments industry’s loss of -9%. The Zacks analyst believes that growing adoption of the da Vinci system, improving procedure volumes, as well as a solid recurring revenue base are some of the major headwinds.
The company’s revenue growth in the second quarter of 2021 indicated procedure growth as well as higher-than-expected system placements. Strong segmental performance was also witnessed during the quarter. Stiff competition in the global MedTech space, increased production cost due to the pandemic and risks related to procedure adoption remain as major concerns though.
(You can read the full research report on Intuitive Surgical here >>>)
Other noteworthy reports we are featuring today include Fidelity National Information Services and FedEx.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.